ALGS — Aligos Therapeutics Share Price
0.000.00%
Last trade - 00:00- $39.34m
- -$73.17m
- $15.53m
- 12
- 41
- 69
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.59 | ||
| Price to Tang. Book | 0.59 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -79.12% | ||
| Return on Equity | -137.79% | ||
| Operating Margin | -625.4% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 4.36 | 13.91 | 15.53 | 0.99 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.
Directors
- Jack Nielsen NEC (57)
- Leonid Beigelman PRE (63)
- Lawrence Blatt CEO (59)
- Lesley Calhoun CFO (55)
- Julian Symons EVP (60)
- Lucinda Quan EVP (48)
- Bridget Martell DRC (55)
- K. Peter Hirth IND (69)
- Peter Moldt IND (62)
- Carole Nuechterlein IND (60)
- James Scopa IND (62)
- Thomas Woiwode IND (49)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 5th, 2018
- Public Since
- October 16th, 2020
- No. of Shareholders
- 46
- No. of Employees
- 67
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 78,109,927
- Address
- One Corporate Dr., 2nd Floor, 2nd Floor, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.aligos.com/
- Phone
- +1 3026587581
- Contact
- Jordyn Tarazi
- Auditors
- Ernst & Young LLP
Upcoming Events for ALGS
Aligos Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Aligos Therapeutics Inc Earnings Release
Q3 2024 Aligos Therapeutics Inc Earnings Release
Similar to ALGS
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Aligos Therapeutics share price?
As of Today at 19:11 UTC, shares in Aligos Therapeutics are trading at $0.45. This share price information is delayed by 15 minutes.
How has the Aligos Therapeutics share price performed this year?
Shares in Aligos Therapeutics last closed at $0.45 and the price had moved by -53.57% over the past 365 days. In terms of relative price strength the Aligos Therapeutics share price has underperformed the S&P500 Index by -63.05% over the past year.
What are the analyst and broker recommendations for Aligos Therapeutics?
The overall consensus recommendation for Aligos Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Aligos Therapeutics dividend yield?
Aligos Therapeutics does not currently pay a dividend.
Does Aligos Therapeutics pay a dividend?
Aligos Therapeutics does not currently pay a dividend.
When does Aligos Therapeutics next pay dividends?
Aligos Therapeutics does not currently pay a dividend.
How do I buy Aligos Therapeutics shares?
To buy shares in Aligos Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aligos Therapeutics?
As of the previous close price of $0.45, shares in Aligos Therapeutics had a market capitalisation of $35.23m.
Where are Aligos Therapeutics shares listed?
Here are the trading details for Aligos Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ALGS
What kind of share is Aligos Therapeutics?
Based on an overall assessment of its quality, value and momentum Aligos Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aligos Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Aligos Therapeutics is $7.00. That is 1452.11% above the last closing price of $0.45.
Analysts covering Aligos Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.73 for the next financial year.
What is the trend in the Aligos Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aligos Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -43.71%.
As of the last closing price of $0.45, shares in Aligos Therapeutics were trading -39.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aligos Therapeutics PE Ratio?
The Aligos Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aligos Therapeutics?
Aligos Therapeutics' management team is headed by:
- Jack Nielsen - NEC
- Leonid Beigelman - PRE
- Lawrence Blatt - CEO
- Lesley Calhoun - CFO
- Julian Symons - EVP
- Lucinda Quan - EVP
- Bridget Martell - DRC
- K. Peter Hirth - IND
- Peter Moldt - IND
- Carole Nuechterlein - IND
- James Scopa - IND
- Thomas Woiwode - IND